MDY Healthcare plc

Appointment of New Directors

12 May 2010: MDY Healthcare plc ("MDY Healthcare" or the "Company"), the strategic investor in healthcare companies, today announces the appointments of Mr Grahame Cook and Mr Martin Hunt as Non-executive Directors with immediate effect.  Derek Ablett, Non-executive Director, will retire from the MDY Healthcare board on 30 June 2010.  In June, the Company will be announcing its interim results for the six months ended 31 March 2010 and will update shareholders further at that time on the Company's strategy. 

Alan MacKay, Chairman, commented, "We are delighted to announce the appointment of two high calibre non-executives to the Board of MDY Healthcare. Both Grahame and Martin have significant sector experience and have an impressive track record of growing revenues for well-known organisations including Bristol-Myers Squibb and Sinclair Pharma. Their combined experience comes at an important stage in the Company's development and we look forward to updating shareholders on MDY's revised strategy at our interim results in June.

"I would also like to take the opportunity to thank Derek Ablett for his contribution to the Company and wish him every success going forward. Derek has agreed to stay with the Company until 30 June 2010 to ensure a smooth transition and handover period."

Grahame Cook is a chartered accountant and has more than 20 years' experience in investment banking in London, Switzerland and Germany. He was a director at Barclays de Zoete Wedd until 1995, then a Managing Director at UBS Investment Banking until 1998 following which he became CEO of West LB Panmure until 2003.

Grahame has significant experience of capital raising, capital structuring and mergers and acquisitions. Since 2003, he has been a non-executive director of a number of companies, including Minoan Group plc, a resort developer, and Antisoma plc, a biotech company specialising in novel drugs for the treatment of cancer. Grahame is the chairman of Sinclair Pharma plc, a skin and mouth disease specialist and the chairman of Fulcrum Pharma PLC, a provider of strategic drug development and regulatory services.

Martin Hunt has spent 28 years in the medtech industry working for both multi-nationals and small to medium size enterprises.  He spent 10 years at American Cyanamid in sales and marketing positions in the fields of pharmaceuticals, wound closure and latterly, ophthalmic surgery as marketing director for Europe, Middle East & Africa.  Martin spent five years at Bristol-Myers Squibb in wound care and stoma therapy as Regional Operations Director and then VP Sales, Europe between 1994 and 1996. 

Martin was a founder of a start-up in the IV infusion field before joining TSL, a company with a novel collagen-based technology, as CEO in 1999.  Under Martin's leadership, TSL was successfully admitted to AIM in 2001 and then sold to Covidien in 2008 at a substantial premium to the share price reflecting significant growth in revenues at TSL.  Since leaving TSL, Martin has continued to be involved in medtech innovations with a number of non-executive director and advisor roles.  These include Orthox Limited, an Oxford spin-out in the field of cartilage repair where he is chairman; Director and advisor at Trophos SA, a French biotech addressing CNS diseases; Programme Director at i4i (a National Institute for Health Research early stage medtech funding programme) and a Venture Partner at H2O Venture Partners in Oxford.

Grahame David Cook, aged 52, is, or has been, a director or partner of the following companies during the previous five years:

Current directorships/partnerships:

Past directorships/partnerships:

There is no further information required to be disclosed pursuant to Schedule 2, paragraph (g) of the AIM Rules for Companies in connection with Mr Cook.

Martin Braddock Hunt, aged 51, is, or has been, a director or partner of the following companies during the previous five years:

Current directorships/partnerships:

Orthox Limited

Invictus Management Limited

Past directorships/partnerships:

Tissue Science Laboratories (UK) Limited

Tissue Science Laboratories Limited

Regentix Limited

There is no further information required to be disclosed pursuant to Schedule 2, paragraph (g) of the AIM Rules for Companies in connection with Mr Hunt.

For further information, please contact:

Notes for editors:

About MDY Healthcare

MDY Healthcare plc is a sector specialised strategic investing company quoted on AIM (ticker symbol: MDY).  The Company seeks to achieve superior returns for shareholders by investing globally in companies, both public and private, across the healthcare sector.  The directors and executives have significant operational and investment experience in the sector and therefore the ability to identify and review a wide range of potential investments.  Further information can be found on the website www.mdyhealthcare.com. 

END